DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qhd373/immunotherapy) has announced the addition of the "Immunotherapy Drugs Market by Type of Drug, Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020" report to their offering.
The immunotherapy drugs market is expected to grow at a CAGR of 12.8% to reach USD 73,529.2 Million by 2020
The growing focus on cancer therapies with fewer side effects is a key factor driving the growth of the global immunotherapy drugs market. Other factors driving the market include high prevalence rate of lifestyle diseases including cancer, fast track and orphan drug designations expediting the review of drugs.
Factors such as high costs of treatment and lesser number of products getting approved are expected to restrict market growth. On the other hand significant growth prospects in the developing economies and high potential of immunotherapy to get approved as first line treatment are the major opportunities in the market.
The immunotherapy drugs market is broadly segmented on the basis of type of drug and geography. The major types of drugs considered include monoclonal antibodies, interferons alpha, interleukins, and vaccines. Among these drugs, monoclonal antibodies are expected to command the largest share while checkpoint Inhibitors is expected to grow at the fastest rate.
Both categories of drugs are targeted therapies which act upon the targets that cannot be captured by small-molecule drugs and precisely identify and attack diseased cells, while doing little damage to normal cells.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Cancer Immunotherapy Market- Industry Insights
7 Immunotherapy Drugs Market, By Type of Drugs
8 Global Immunotherapy Drugs Market, By Region
9 Competitive Landscape
10 Company Profiles
- Amgen Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- ELI Lilly and Company
- F. Hoffmann-La Roche Ag
- Glaxosmithkline Plc
- Merck & Co., Inc.
- Novartis International Ag
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/qhd373/immunotherapy